New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.
Asya Nina Varshavsky-Yanovsky, MD, PhD
Advertisement
Asya Nina Varshavsky-Yanovsky, MD, PhD, is an associate professor in the Department of Bone Marrow Transplant and Cellular Therapies at Fox Chase Cancer Center.
Articles by Asya Nina Varshavsky-Yanovsky, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
ATTR-CM Incidence, Prevalence Rose Sharply in the US
4
Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS
5